LKS Next Corporate supports Inmolecule in its stock market debut on Euronext Access Paris

by LKS Next

Headquartered in Madrid and founded in 1999, Inmolecule has developed a patented technology platform that creates nanoparticles of active ingredients for sectors such as personal care, home care, agri...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Telum Therapeutics Secures €18 Million...

by Inveready Asset Management

Telum Therapeutics, a biotechnology company leveraging proprietary met...

Photos Stream